These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The pharmacology of isamoxole [2-methyl-n-butyl-n(4-methyloxazol-2-yl) propanamide] LRCL 3950, a new anti-allergic compound.
    Author: Dawson W, Sweatman WJ.
    Journal: Br J Pharmacol; 1980; 71(2):387-98. PubMed ID: 6781575.
    Abstract:
    1. Isamoxole [2-methyl-N-butyl-N(4-methyloxazol-2-yl) propanamide] is an effective orally active anti-allergic compound in animals. 2. Isamoxole inhibits the immunological release of mediators, notably slow-reacting substance of anaphylaxis (SRS-A) from sensitized human and guinea-pig chopped lung in vitro. 3. In vivo, allergic responses were inhibited in guinea-pigs and rats by doses as low as 25 mg/kg given orally 180 and 30 min before challenge. The effect of Isamoxole was still present 4 h after a single dose of 100 mg/kg orally in the guinea-pig and 3 h in the rat. 4. Isamoxole is a moderately potent, selective inhibitor of SRS-A activity on the guinea-pig ileum in vitro, at concentrations that do not antagonize histamine, 5-hydroxytryptamine, or bradykinin. 5. Isamoxole causes human bronchial muscle to relax and antagonizes the bronchoconstriction induced by SRS-A.
    [Abstract] [Full Text] [Related] [New Search]